NeuMoDx Molecular Revenue and Competitors
Estimated Revenue & Valuation
- NeuMoDx Molecular's estimated annual revenue is currently $22.1M per year.
- NeuMoDx Molecular received $20.0M in venture funding in May 2016. 0
- NeuMoDx Molecular's total funding is $66M.
Employee Data
- 00
NeuMoDx Molecular Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1M | 4 | N/A | N/A | N/A |
#2 | $43.2M | 172 | -9% | N/A | N/A |
#3 | $7M | 28 | -10% | N/A | N/A |
#4 | $214.6M | 855 | 0% | N/A | N/A |
#5 | $6.5M | 26 | 0% | N/A | N/A |
#6 | $11.5M | 46 | 0% | N/A | N/A |
#7 | $4M | 16 | N/A | N/A | N/A |
#8 | $4.3M | 17 | -37% | N/A | N/A |
#9 | $25.4M | 101 | -9% | N/A | N/A |
#10 | $22.1M | 0 | N/A | $66M | N/A |
What Is NeuMoDx Molecular?
$66M
Total Funding
N/A
Number of Employees
$22.1M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
NeuMoDx Molecular News
NeuMoDx Molecular, Inc., an Ann Arbor, MI-based diagnostics company developing a new platform for high throughput, low cost molecular testing, raised $21m in Series B financing. The round was led by Pfizer Ventures with participation from Baird Capital, Venture Investors and existing investors ...
Baird Capital co-led a $21 million Series B financing in NeuMoDx Molecular Inc., a diagnostics company developing a new platform for high-efficiency, low-cost molecular testing. “Molecular diagnostic testing continues to be an attractive investment area for us and we look forward to working with ...
Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top ...
NEW YORK – NeuMoDx has filed a response with the District of ... by Becton Dickinson that the molecular diagnostics developer infringed on ...
1.1.8.2.1.1 Lab-on-a-chip and Molecular Biology ... Cancer Therapy; QIAGEN NV Selects NeuMoDx Molecular, Inc for CE-IVD Assays Purchase ...
BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced an expansion ...
Other Companies in Ann Arbor
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.7M | 0 | N/A | $31.2M |
#2 | $133.4M | 0 | N/A | $1.4M |
#3 | $6.2M | 0 | N/A | $427M |
#4 | $7.6M | 0 | N/A | $12.4M |
#5 | $212.7M | 0 | N/A | $13.4M |
NeuMoDx Molecular Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-03-28 | $10.5M | Undisclosed | Article | |
| 2014-04-02 | $21.0M | B | Pfizer Ventures | Article |
| 2016-05-03 | $20.0M | Undisclosed | Article |
